Viking Therapeutics
VKTX
144 hedge funds and large institutions have $260M invested in Viking Therapeutics in 2021 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 50 increasing their positions, 43 reducing their positions, and 20 closing their positions.
291% more call options, than puts
Call options by funds: $8.57M | Put options by funds: $2.19M
22% more capital invested
Capital invested by funds: $212M → $260M (+$47.5M)
16% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 43
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
4.29% more ownership
Funds ownership: 51.73% → 56.03% (+4.3%)
1% more funds holding
Funds holding: 143 → 144 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$12M |
| 2 |
Two Sigma Investments
New York
|
+$5.86M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.1M |
| 4 |
Two Sigma Advisers
New York
|
+$3.96M |
| 5 |
Citigroup
New York
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$6.04M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$2.46M |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$1.82M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.35M |
| 5 |
Renaissance Technologies
New York
|
-$1.01M |
VKTX Hedge Fund Activity: Q1 2021 in Review
144 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q1 2021, worth a combined $260M — up 22% from $212M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new VKTX positions and 20 closed out — a net gain of 2 holders — while 50 added to existing stakes and 43 trimmed.
The largest buyer was State Street, adding an estimated $12M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $6.04M.
- 144 institutional investors held Viking Therapeutics (VKTX) as of Q1 2021, up from 143 in Q4 2020.
- Funds reported $260M of Viking Therapeutics stock for Q1 2021, up 22% quarter-over-quarter.
- 22 funds opened new Viking Therapeutics positions in Q1 2021 and 20 closed out, a net change of +2 holders.
- The largest Viking Therapeutics buyer in Q1 2021 was State Street, an estimated $12M added.
- The largest Viking Therapeutics seller in Q1 2021 was ArrowMark Colorado Holdings, an estimated $6.04M sold.
Based on aggregated 13F filings for Q1 2021.